Morgan Stanley Downgrades Arcus Biosciences to Equal-Weight, Lowers Price Target to $20
Benzinga Newsdesk 10 months ago
NewsDowngradesPrice TargetAnalyst Ratings
Morgan Stanley analyst Terence Flynn downgrades Arcus Biosciences (NYSE:RCUS) from Overweight to Equal-Weight and lowers the price target from $23 to $20.
Morgan Stanley analyst Terence Flynn downgrades Arcus Biosciences (NYSE:RCUS) from Overweight to Equal-Weight and lowers the price target from $23 to $20.